

***Staphylococcus aureus* (MRSA), Strain COL, Gateway® Clone Set, Recombinant in *Escherichia coli*, Plates 1-25**

Catalog No. NR-19277

For research use only. Not for human use.

This reagent is the tangible property of the U.S. Government.

Contributor:

Pathogen Functional Genomics Resource Center at the J. Craig Venter Institute

Manufacturer:

BEI Resources

Product Description:

Clone plates are replicated using a BioMek® FX robot. Production in the 96-well format has increased risk of cross-contamination between adjacent wells. Individual clones should be purified (e.g. single colony isolation and purification using good microbiological practices) and sequence-verified prior to use. BEI Resources only confirms the clone plate orientation and viability of randomly picked clones. BEI Resources does not confirm or validate individual clone identities provided by the contributor.

NR-19277 consists of Plates 1-25 (BEI Resources NR-19497 through NR-19521) of the *Staphylococcus aureus* (MRSA), strain COL, Gateway® clone set. Detailed information is available on the Product Information Sheet and Master Clone List.

The methicillin-resistant *Staphylococcus aureus* (*S. aureus*), strain COL, Gateway® clone set consists of 25 plates which contain approximately 2343 sequence validated clones from *S. aureus* strain COL cloned in *Escherichia coli* (*E. coli*) DH10B-T1 cells. Each open reading frame was constructed in vector pDONR™221 (Invitrogen™) with a native start codon and no stop codon. The sequence was validated by full length sequencing of each clone with greater than 1X coverage and a mutation rate of less than 0.2%.

Information related to the use of Gateway® Clones can be obtained from [Invitrogen™](#). Recombination was facilitated through an *attB* substrate (*attB*-PCR product or a linearized *attB* expression clone) with an *attP* substrate (pDONR™221) to create an *attL*-containing entry clone. The entry clone contains recombinational cloning sites, *attL1* and *attL2* to facilitate gene transfer into a destination vector, M13 forward and reverse priming sites for sequencing and a kanamycin resistance gene for selection. Please refer to the [Invitrogen™ Gateway® Technology Manual](#) for additional details.

Plate orientation and viability were confirmed for each plate of the set.

Material Provided:

Every inoculated well of each 96-well plate contains approximately 60 µL of *E. coli* culture (strain DH10B-T1) in Luria Bertani (LB) broth containing 50 µg/mL kanamycin supplemented with 15% glycerol.

Packaging/Storage:

NR-19277 was packaged aseptically in 96-well plates. The product is provided frozen and should be stored at -80°C or colder immediately upon arrival. For long-term storage, the vapor phase of a liquid nitrogen freezer is recommended. Freeze-thaw cycles should be avoided.

Growth Conditions:

Media:

LB broth containing 50 µg/mL kanamycin

LB agar containing 50 µg/mL kanamycin

Incubation:

Temperature: 37°C

Atmosphere: Aerobic

Propagation:

1. Scrape top of frozen well with a pipette tip and streak onto agar plate.
2. Incubate the plates at 37°C for 18 to 24 hours.

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: *Staphylococcus aureus* (MRSA), Strain COL, Gateway® Clone Set, Recombinant in *Escherichia coli*, Plates 1-25, NR-19277."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. [Biosafety in Microbiological and Biomedical Laboratories](#), 5th ed. Washington, DC: U.S. Government Printing Office, 2009; see www.cdc.gov/biosafety/publications/bmb15/index.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been

confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Gill, S. R., et al. "Insights on Evolution of Virulence and Resistance from the Complete Genome Analysis of an Early Methicillin-Resistant *Staphylococcus aureus* Strain and a Biofilm-Producing Methicillin-Resistant *Staphylococcus epidermidis* Strain." J. Bacteriol. 187 (2005): 2426-2438. PubMed: 15774886.

ATCC® is a trademark of the American Type Culture Collection.

